AQST
Aquestive Therapeutics, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.94-4.25%
Price as of Jul 20, 2026
AQST financials
Aquestive Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M |
| Cost of revenue | $17.2M | $17.9M | $20.8M | $19.4M |
| Gross profit | $27.4M | $39.7M | $29.8M | $28.3M |
| Operating expenses | $97.0M | $70.5M | $44.9M | $70.4M |
| Operating income | -$69.7M | -$30.8M | -$15.1M | -$42.1M |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M |
| EBITDA | -$66.1M | -$26.6M | $1.2M | -$39.6M |
| Basic EPS | $-0.76 | $-0.51 | $-0.13 | $-1.12 |
| Diluted EPS | $-0.76 | $-0.51 | $-0.13 | $-1.12 |
| Balance sheet | ||||
| Cash & equivalents | $121.2M | $71.5M | $23.9M | $27.3M |
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M |
| Stockholders’ equity | -$33.7M | -$60.2M | -$106.5M | -$118.6M |
| Total debt | $131.4M | $38.0M | $33.3M | $57.5M |
| Net debt | $10.3M | -$33.5M | $9.4M | $30.2M |
| Cash flow | ||||
| Operating cash flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M |
| Capital expenditure | -$562.0K | -$159.0K | -$995.0K | -$2.5M |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$12.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |